count and cell predominance is variable. Characteristic multinucleated macrophages and necrotic background debris may be seen. Here, the pleural aspiration was not definitive in determining aetiology. Cytology confirmed large numbersof acute inflammatorycells accompanied by macrophages and mesothelial cells. Occasional multinucleated giant cells were seen; these have been described in both tuberculous and rheumatoid effusions.Noalcohol/acid fastbacilli werecultured.Asample was sent for adenosine deaminase (ADA). Low ADA excludes tuberculous effusion however it is recognised that in rheumatoid disease it may be elevated. The ADA was elevated at 69 IU/L (0 -45). If the diagnosis remains unclear, as in this case, histological examination of the pleura may reveal replacement of the normal mesothelial lining with multinucleated giant cells and foci of palisading fibroblasts and lymphocytes surrounding necrotic centres, similar to rheumatoid nodules. This gentleman's biopsy demonstrated fibrinous pleuritis with chronic inflammation and some patchy mesothelial hyperplasia and no evidence of granulomatous inflammation. The pathologist stated that these appearances are observed in patients with rheumatoid arthritis but are not specific. Most cases of rheumatoid pleuritis improve with treatment of the underlying arthritis; small, asymptomatic effusions don't require specific intervention. However, persistent effusion can lead to pleural thickening and trapped lung; this would suggest that those with large or persistent effusion should be treated to avoid complication. Key learning points: This patient developed a pleural effusion concurrent with sepsis, which persisted post infection and also experienced recurrent chest sepsis (although not as severe at time of admission) over the following 6-9 months. The effusion progressed with time in parallel with joint activity. The persistence of effusion was likely on the basis of RA, and establishing that this was the driving factor once infection/ other aetiology was excluded led to re-evaluation regarding biologic therapy with multi-specialty input. After such significant infection and prolonged period of recovery and investigation, without resolution of the effusion, the patient, the rheumatology and the respiratory teams were each apprehensive about escalating immunosuppressive therapy. Initially, no further treatment with biologic was agreed. However, after several years of moderate ongoing disease activity and then significant flare, the cautious use of biologic agent was reconsidered. At this time, the patient's quality of life was substantially diminished by his joint disease, and he made an educated decision to consent to treatment with abatacept. The BSR biologic DMARD safety guidelines in inflammatory arthritis recommend using etanercept or abatacept as a first line biologic therapy in patients at high risk of infection, whilst American College of Rheumatology guideline regarding patients with RA and previous serious infection strongly recommendsabatacept over TNF-a antagonist. An increased risk of TB has been observed in patients receiving TNF-a antagonist. The British Societyfor Rheumatology (BSR) guideline regarding biologic DMARD in inflammatory arthritis recommends that all patients should be screened for latent TB with IGRA and chest radiograph, and treatedprior to commencing treatment. Conflict of interest: The authors declare no conflicts of interest.
CMV REACTIVATION IN REFRACTORY ANCA-ASSOCIATED VASCULITIS
Neelam Hassan 1 , and Harsha Gunawardena 1 1 Rheumatology, North Bristol NHS Trust, Bristol, United Kingdom Introduction:The anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitides are a heterogeneous group of rare multisystem disorders characterised by inflammation and necrosis of small and medium blood vessels. Early diagnosis and prompt initiation of immunosuppressive treatment are essential to induce and maintain remission of disease, and therebyprevent severe life-or organ-threatening complications. We present a challenging case of a patient presenting with progressive lung lesions in the context of known ANCA-associated vasculitis (AAV), despite escalating immunosuppressive treatment. Case description: A 66-year old-female was diagnosed in 2010 with cANCA (PR3) positive vasculitis with lung involvement. Remission was induced with high dose steroids and cyclophosphamide. Methotrexate was givenas maintenance treatmentuntil2013 whenshehadasignificant renal relapse treated with plasma exchange,steroids and cyclophosphamide. Her maintenance treatment was changed to mycophenolate. She had a further lung relapse in 2014, treated successfully with high dose steroids and rituximab.She was eventually weaned off all treatment in 2017. She was admitted to hospital in 2019 with dry cough, dyspnoea and sinus congestion. She was noted to have several purpuric lesions on her limbs. Her CRP was elevated at 123 with a stable eGFR of 77. ANCA screen was negative. Chest Xray revealed bilateral consolidation. She was initially treated with six pulses of 500mg of IV methylprednisolone and one pulse of rituximab as an inpatient over the course of 2 weeks, with broad spectrum antibiotic cover. Despite this, she continued to deteriorate with a worsening purpuric rash and increasing oxygen requirement. She underwent plasma exchange with little improvement. CT of her chest revealed multiple progressive bilateralcavitating lesions. It was noted that her IgG levels were low (3.72) following rituximab, increasing her risk of infection. An atypical infection screen was performed and she was discovered to have cytomegalovirus(CMV)reactivation with high viral titres of 56889. She underwent bronchoscopic alveolar lavage which was positive for CMV on PCR. CT guided lung biopsy revealed necrotising granulomatous inflammation with occasional CMV positive nuclei. She was given valganciclovir and IV immunoglobulin, and her prednisolone dose was reduced to 10mg. This resulted in her viral load reducing to undetectable levels, her CRP improving to 23 and immunoglobulins normalising. This correlated with a clinical improvement allowing the patient to be discharged home. Discussion: The patient in this case appeared in the first instance to have another flare of her AAV. However the flare was atypical in that it was not associated with an increase in her cANCA titre and it did not respond quickly to steroids as had been the case on each previous occasion. This prompted a reassessment of her case and investigation into other potential causes for her deterioration. CMV is a persistent herpesvirus which can affect up to 75% of healthy individuals. The primary infection is rarely symptomatic but can be associated with significant morbidity and mortality in immunocompromised patients. Pulmonary CMV disease can mimic pulmonary disease associated with vasculitis. CMV can also directly damage endothelial cells and cause an occlusive vasculitis itself. The patient was immunosuppressed, increasing her risk of acquiring primary CMV infection or developing CMV reactivation. She was given further potent immunosuppression during her admission. Serology is often unreliable in immunosuppressed patients and in this case her CMV IgG was positive with a negative IgM, indicating past CMV infection only. It is important to send samples for viral PCR to detect and diagnose active infection, and allow treatment to be initiated promptly. The lung biopsy was felt to be more in keeping with active AAV, although occasional CMV positive nuclei were present. The patient was therefore managed as having CMVreactivation in the context of active AAV. Treatment of viral infection can pose further challenges when trying to manage coexistent active vasculitis as highlighted in this case. Close monitoring of the patient was required, together with a multidisciplinary approach involving input from colleagues in infectious diseases and immunology, to allow the patient to be managed safely and effectively. Prophylactic antiviral therapy may need to be considered if further immunosuppression is required in future. Introduction: Interstitial lung disease (ILD) can occur in any connective tissue disease, with varying degrees of respiratory clinical manifestations. In the majority of cases, patients have an established connective tissue diagnosis that precedes the development of ILD by many years. This discussion will focus on the unusual presentation of an 18 year old female admitted with a short history of weight loss and breathlessness. Investigations showed extensive established ILD with strongly positive autoantibodies, but in the absence of clinical signs of an underlying connective tissue disorder apart from Raynaud's phenomenon. Case description:18-year-old female presented with athree-month history of unintentional 25kg weight loss, six weeks of fatigue/malaise, and a two-week history of worsening breathlessness. She was a student, non-smoker, with no past medical history except for class I obesity, and not on regular medications. On examination she had fine bibasal end-inspiratory crackles, SaO2 96% RA and Raynaud's phenomenon was observed. Her CXR demonstrated bibasal consolidation. CT imaging identified bilateral symmetrical peripheral patchy ground glass opacities and patchy consolidation with basal predominance. Bloods revealed rheumatoid factor 491.2, anti-i10 27 September 2019 ORAL PRESENTATIONS
